Risks and benefits of current and novel drugs to treat agitation in Alzheimer’s disease

References

• Weller J, Budson A. Current understanding of Alzheimer’s disease diagnosis and treatment. F1000Res. 2018;7:1161.
   Google Scholar
• Collaborators GDF. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019. Lancet Public Health. 2022;7(2):e105–e25.
   PubMed Web of Science ®Google Scholar
• 2020 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia. 2020;16(3): 391–460.
   Web of Science ®Google Scholar
• Steinberg M, Shao H, Zandi P, et al., Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the cache county study. Int J Geriatr Psychiatry. 2008;23(2):170–177.
   PubMed Web of Science ®Google Scholar
• Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol. 2012;3:73.
   PubMedGoogle Scholar
• Kwon CY, Lee B. Prevalence of behavioral and psychological symptoms of dementia in community-dwelling dementia patients: a systematic review. Front Psychiatry. 2021;12:741059.
   PubMed Web of Science ®Google Scholar
• Carrarini C, Russo M, Dono F, et al. Agitation and dementia: prevention and treatment strategies in acute and chronic conditions. Front Neurol. 2021;12:644317.
   PubMed Web of Science ®Google Scholar
• Cummings J, Mintzer J, Brodaty H, et al., Agitation in cognitive disorders: international psychogeriatric association provisional consensus clinical and research definition. Int Psychogeriatr. 2015. 27(1): 7–17.
   PubMed Web of Science ®Google Scholar
• Okura T, Plassman BL, Steffens DC, et al. Neuropsychiatric symptoms and the risk of institutionalization and death: the aging, demographics, and memory study. J Am Geriatr Soc. 2011;59(3):473–481.
   PubMed Web of Science ®Google Scholar
• Kolanowski A, Boltz M, Galik E, et al. Determinants of behavioral and psychological symptoms of dementia: a scoping review of the evidence. Nurs Outlook. 2017;65(5):515–529.
   PubMed Web of Science ®Google Scholar
• Millán-Calenti JC, Lorenzo-López L, Alonso-Búa B, et al. Optimal nonpharmacological management of agitation in Alzheimer’s disease: challenges and solutions. Clin Interv Aging. 2016;11:175–184.
   PubMed Web of Science ®Google Scholar
• Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015; 350:h369. mar02 7
   PubMed Web of Science ®Google Scholar
• Simonetti A, Pais C, Jones M, et al. Neuropsychiatric symptoms in elderly with dementia during COVID-19 pandemic: definition, treatment, and future directions. Front Psychiatry. 2020;11:579842.
   PubMed Web of Science ®Google Scholar
• Ijaopo EO. Dementia-related agitation: a review of non-pharmacological interventions and analysis of risks and benefits of pharmacotherapy. Transl Psychiatry. 2017;7(10):e1250.
   PubMedGoogle Scholar
• Livingston G, Kelly L, Lewis-Holmes E, et al. Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials. Br J Psychiatry. 2014;205(6):436–442.
   PubMed Web of Science ®Google Scholar
• Salzman C, Jeste DV, Meyer RE, et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry. 2008;69(6):889–898.
   PubMed Web of Science ®Google Scholar
• Kales HC, Gitlin LN, Lyketsos CG. Dementia DEPoAaMoNSo. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014;62(4):762–769.
   PubMed Web of Science ®Google Scholar
• Manzano-Palomo S, Agüera-Ortiz LF, García-Caballero A, et al. Use of antipsychotics in patients with behavioral and psychological symptoms of dementia: results of a Spanish Delphi consensus. Dement Geriatr Cogn Disord. 2020;49(6):573–582.
   PubMed Web of Science ®Google Scholar
• Sano M, Soto M, Carrillo M, et al. Identifying better outcome measures to improve treatment of agitation in dementia: a report from the EU/US/CTAD task force. J Prev Alzheimers Dis. 2018;5(2):98–102.
   PubMed Web of Science ®Google Scholar
• Pascualy M, Petrie E, Wang LY, et al. Chapter 73: Management of agitation in dementia. In: Halter JB, Ouslander JG, Tinetti ME , et al., editors. Hazzard’s geriatric medicine and gerontology. Edition 6. New York NY: The McGraw-Hill Companies; 2009. p. 873–882.
   Google Scholar
• Mühlbauer V, Möhler R, Dichter MN, et al. Antipsychotics for agitation and psychosis in people with Alzheimer’s disease and vascular dementia. Cochrane Database Syst Rev. 2021;12. DOI: 10.1002/14651858.CD013304.pub2. CD013304.
   PubMedGoogle Scholar
• Kirkham J, Sherman C, Velkers C, et al. Antipsychotic Use in Dementia. Can J Psychiatry. 2017;62(3):170–181.
   PubMed Web of Science ®Google Scholar
• Maust DT, Langa KM, Blow FC, et al. Psychotropic use and associated neuropsychiatric symptoms among patients with dementia in the USA. Int J Geriatr Psychiatry. 2017;32(2):164–174.
   PubMed Web of Science ®Google Scholar
• Shah SM, Carey IM, Harris T, et al. Antipsychotic prescribing to older people living in care homes and the community in England and Wales. Int J Geriatr Psychiatry. 2011;26(4):423–434.
   PubMed Web of Science ®Google Scholar
• Rios S, Perlman CM, Costa A, et al. Antipsychotics and dementia in Canada: a retrospective cross-sectional study of four health sectors. BMC Geriatr. 2017;17(1):244.
   PubMedGoogle Scholar
• Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev. 2001;4:CD002852.
   Google Scholar
• Yunusa I, El Helou ML. The use of risperidone in behavioral and psychological symptoms of dementia: a review of pharmacology, clinical evidence, regulatory approvals, and off-label use. Front Pharmacol. 2020;11:596.
   PubMed Web of Science ®Google Scholar
• Tampi RR, Tampi DJ, Balachandran S, et al. Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis. 2016;7(5):229–245.
   PubMed Web of Science ®Google Scholar
• Grossberg GT, Kohegyi E, Mergel V, et al. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer’s Dementia: two 12-week, randomized, double-blind, placebo-controlled trials. Am J Geriatr Psychiatry. 2020;28(4):383–400.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Mechanism of action of pimavanserin in Parkinson’s disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors. CNS Spectr. 2016;21(4):271–275.
   PubMed Web of Science ®Google Scholar
• Ballard CG, Coate B, Abler V, et al. Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer’s disease psychosis: a post hoc analysis. Int J Geriatr Psychiatry. 2020;35(11):1402–1408.
   PubMed Web of Science ®Google Scholar
• Today AsN. Nuplazid (Pimavanserin). BioNews, Inc; [cited 2022 Jun 1]. Available from: https://alzheimersnewstoday.com/pimavanserin/.
   Google Scholar
• Tariot PN, Cummings JL, Soto-Martin ME, et al. Trial of pimavanserin in dementia-related psychosis. N Engl J Med. 2021;385(4):309–319.
   PubMed Web of Science ®Google Scholar
• Greenwood J, Acharya RB, Marcellus V, et al. Lumateperone: a novel antipsychotic for schizophrenia. Ann Pharmacother. 2021;55(1):98–104.
   PubMed Web of Science ®Google Scholar
• Intra-cellular therapies announces update on ITI-007-201 clinical trial for treatment of agitation in patients with probable Alzheimer’s disease. New York: GlobeNewswire; 2018. cited 2022 Jun 1]. Available from: https://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-announces-update-iti-007-201-clinical
   Google Scholar
• Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682–691.
   PubMed Web of Science ®Google Scholar
• FDA drug safety communication: revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. U.S. Food and Drug Administration; 2012. cited 2022 Jun 30]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related.
   Google Scholar
• Ho T, Pollock BG, Mulsant BH, et al. R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. Br J Clin Pharmacol. 2016;82(3):784–792.
   PubMed Web of Science ®Google Scholar
• Ehrhardt S, Porsteinsson AP, Munro CA, et al. Escitalopram for agitation in Alzheimer’s disease (S-CitAD): methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial. Alzheimers Dement. 2019;15(11):1427–1436.
   PubMed Web of Science ®Google Scholar
• Liu CS, Chau SA, Ruthirakuhan M, et al. Cannabinoids for the treatment of agitation and aggression in Alzheimer’s disease. CNS Drugs. 2015;29(8):615–623.
   PubMed Web of Science ®Google Scholar
• Sherman C, Ruthirakuhan M, Vieira D, et al. Cannabinoids for the treatment of neuropsychiatric symptoms, pain and weight loss in dementia. Curr Opin Psychiatry. 2018;31(2):140–146.
   PubMed Web of Science ®Google Scholar
• Ruthirakuhan M, Lanctôt KL, Vieira D, et al. Natural and synthetic cannabinoids for agitation and aggression in Alzheimer’s disease: a meta-analysis. J Clin Psychiatry. 2019;80(2). 10.4088/JCP.18r12617.
   PubMed Web of Science ®Google Scholar
• Volicer L, Stelly M, Morris J, et al. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. Int J Geriatr Psychiatry. 1997;12(9):913–919.
   PubMed Web of Science ®Google Scholar
• Woodward MR, Harper DG, Stolyar A, et al. Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms. Am J Geriatr Psychiatry. 2014;22(4):415–419.
   PubMed Web of Science ®Google Scholar
• Cohen LM, Ash E, Outen JD, et al. Study rationale and baseline data for pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer’s dementia (THC-AD). Int Psychogeriatr 2021 1–6 10.1017/S1041610221001150
   PubMed Web of Science ®Google Scholar
• Outen J, Rosenberg P, Vandrey R, et al. Pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer’s disease (THC-AD). Am J Geriatric Psychiatry. 2021;29(4, Supplement):S115–S7.
   PubMed Web of Science ®Google Scholar
• Herrmann N, Ruthirakuhan M, Gallagher D, et al. Randomized placebo-controlled trial of nabilone for agitation in Alzheimer’s disease. Am J Geriatr Psychiatry. 2019;27(11):1161–1173.
   PubMed Web of Science ®Google Scholar
• van den Elsen GA, Ahmed AI, Verkes RJ, et al. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial. Neurology. 2015;84(23):2338–2346.
   PubMed Web of Science ®Google Scholar
• Olney N, Rosen H. AVP-923, a combination of dextromethorphan hydrobromide and quinidine sulfate for the treatment of pseudobulbar affect and neuropathic pain. IDrugs. 2010;13(4):254–265.
   PubMedGoogle Scholar
• Cummings JL, Lyketsos CG, Peskind ER, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. JAMA. 2015;314(12):1242–1254.
   PubMed Web of Science ®Google Scholar
• Schoedel KA, Morrow SA, Sellers EM. Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect. Neuropsychiatr Dis Treat. 2014;10:1161–1174.
   PubMed Web of Science ®Google Scholar
• Liu Z, Ren X, Wang P. A practical synthesis of deuterated methylamine and dimethylamine. J Chem Res. 2020;45:174751982096963.
   Web of Science ®Google Scholar
• Payesko J. Avanir reports phase 3 data of AVP-786 for agitation in Alzheimer disease; 2019 [cited 2022 Jun 1]. Available from: https://www.neurologylive.com/view/endovascular-therapy-shows-better-functional-outcomes-acute-stroke
   Google Scholar
• Wilkinson ST, Sanacora G. A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems. Drug Discov Today. 2019;24(2):606–615.
   PubMed Web of Science ®Google Scholar
• Axsome. AXS-05: a new approach to treating multiple CNS conditions; [cited 2022 Jul 1]. Available from: https://www.globenewswire.com/en/news-release/2022/05/31/2453148/33090/en/Axsome-Therapeutics-Announces-Publication-of-Pivotal-GEMINI-Phase-3-Trial-of-AXS-05-in-Major-Depressive-Disorder-in-The-Journal-of-Clinical-Psychiatry.html
   Google Scholar
• O’Gorman C, Jones A, Cummings JL, et al. Efficacy and safety of AXS-05, a novel, oral, NMDA-receptor antagonist with multimodal activity, in agitation associated with Alzheimer’s disease: results from ADVANCE-1, a phase 2/3, double-blind, active and placebo-controlled trial. Alzheimers Dement. 2020;16(S9):e047684.
   Google Scholar
• Banerjee S, High J, Stirling S, et al. Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. Lancet. 2021;398(10310):1487–1497.
   PubMed Web of Science ®Google Scholar
• Devanand DP, Crocco E, Forester BP, et al. Low dose lithium treatment of behavioral complications in Alzheimer’s disease: lit-AD randomized clinical trial. Am J Geriatr Psychiatry. 2022;30(1):32–42.
   PubMed Web of Science ®Google Scholar
• Wang H, Raleigh DP. General amyloid inhibitors? A critical examination of the inhibition of IAPP amyloid formation by inositol stereoisomers. PLoS One. 2014;9(9):e104023.
   PubMed Web of Science ®Google Scholar
• Lemke MR. Effect of carbamazepine on agitation in Alzheimer’s inpatients refractory to neuroleptics. J Clin Psychiatry. 1995 Aug;56(8):354–357.
   PubMed Web of Science ®Google Scholar
• Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998 Jan;155(1):54–61.
   PubMed Web of Science ®Google Scholar
• Tariot PN, Schneider LS, Cummings J, et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry. 2011 Aug;68(8):853–861.
   PubMed Web of Science ®Google Scholar
• Gallagher D, Herrmann N. Antiepileptic drugs for the treatment of agitation and aggression in dementia: do they have a place in therapy? Drugs. 2014 Oct;74(15):1747–1755.
   PubMed Web of Science ®Google Scholar
• Gauthier S, Patterson C, Chertkow H, et al. Recommendations of the 4th Canadian consensus conference on the diagnosis and treatment of dementia (CCCDTD4). Can Geriatr J. 2012 Dec;15(4):120–126.
   PubMedGoogle Scholar
• Herrmann N, Lanctôt KL, Hogan DB. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian consensus conference on the diagnosis and treatment of dementia 2012. Alzheimers Res Ther. 2013 Jul 8;5(Suppl 1):S5.
   PubMed Web of Science ®Google Scholar
• Read SH, Giannakeas V, Pop P, et al. Evidence of a gabapentinoid and diuretic prescribing cascade among older adults with lower back pain. J Am Geriatr Soc. 2021 Oct;69(10):2842–2850.
   PubMed Web of Science ®Google Scholar
• Ruthirakuhan M, Lanctôt KL, Di Scipio M, et al. Biomarkers of agitation and aggression in Alzheimer’s disease: a systematic review. Alzheimers Dement. 2018;14(10):1344–76.68.
   PubMed Web of Science ®Google Scholar
• Knuff A, Leung RH, Seitz DP, et al. Use of actigraphy to measure symptoms of agitation in dementia. Am J Geriatr Psychiatry. 2019;27(8):865–869.
   PubMed Web of Science ®Google Scholar
• Tumati S, Herrmann N, Marotta G, et al. Blood-based biomarkers of agitation in Alzheimer’s disease: advances and future prospects. Neurochem Int. 2022;152:105250.
   PubMed Web of Science ®Google Scholar
• Guseva E, Iaboni A, Hermann N, et al. Wearable sensor technology for assessment and monitoring of neuropsychiatric symptoms of dementia-systematic review – Are we there yet? 6th Annual McGill Family Medicine Research Symposium, May 13-14, 2021. 2021.
   Google Scholar
• Sanders RD, Hussell T, Maze M. Sedation & immunomodulation. Crit Care Clin. 2009;25(3):551–70, ix.
   PubMed Web of Science ®Google Scholar
• Nitchingham A, Caplan GA. Current challenges in the recognition and management of delirium superimposed on dementia. Neuropsychiatr Dis Treat. 2021;17:1341–1352.
   PubMed Web of Science ®Google Scholar